NASDAQ:PETX Aratana Therapeutics (PETX) Stock Price, News & Analysis → Like Investing in Big Tech in the Early 2000s? (From Manward Press) (Ad) Free PETX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.92▼$4.9250-Day Range$4.92▼$4.9252-Week Range$3.30▼$7.16VolumeN/AAverage Volume1.03 million shsMarket Capitalization$241.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aratana Therapeutics alerts: Email Address Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Aratana Therapeutics Stock (NASDAQ:PETX)Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.Read More Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… PETX Stock News HeadlinesSeptember 9, 2023 | finance.yahoo.comAratana's Drug Pipeline Suggests Revenue Growth Could Continue For YearsAugust 20, 2022 | investing.comPETX_old Historical DataFebruary 19, 2022 | thestreet.comBiotech Premarket Movers: Editas, Amphastar, Aratana, PaciraJanuary 14, 2022 | thestreet.com5 Stocks Under $10 to Trade for Big BreakoutsOctober 26, 2021 | finance.yahoo.comAratana (PETX) Tops Q3 Earnings and Revenue EstimatesSee More Headlines Receive PETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today6/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PETX CUSIPN/A CIK1509190 Webwww.aratana.com Phone913-353-1000FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,720,000.00 Net Margins-33.47% Pretax MarginN/A Return on Equity-12.99% Return on Assets-10.82% Debt Debt-to-Equity RatioN/A Current Ratio6.66 Quick Ratio5.32 Sales & Book Value Annual Sales$35.41 million Price / Sales6.81 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book2.38Miscellaneous Outstanding Shares49,000,000Free FloatN/AMarket Cap$241.08 million OptionableOptionable Beta1.40 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Craig A. Tooman (Age 53)Pres, CEO & Board Director Ms. Rhonda L. Hellums (Age 47)CFO & Treasurer Mr. John C. Ayres J.D. (Age 40)VP of Corp. Devel. and Admin., Gen. Counsel & Sec. Mr. Brent A. Standridge (Age 61)Consultant Ms. Rachel ReiffHead of Corp. CommunicationsKey CompetitorsCureVacNASDAQ:CVACImmunomeNASDAQ:IMNMCentessa PharmaceuticalsNASDAQ:CNTAGyre TherapeuticsNASDAQ:GYREOPKO HealthNASDAQ:OPKView All Competitors PETX Stock Analysis - Frequently Asked Questions How were Aratana Therapeutics' earnings last quarter? Aratana Therapeutics Inc (NASDAQ:PETX) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative trailing twelve-month return on equity of 12.99%. What other stocks do shareholders of Aratana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP), Corcept Therapeutics (CORT), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Ayala Pharmaceuticals (ADXS), Aurinia Pharmaceuticals (AUPH) and Progenics Pharmaceuticals (PGNX). This page (NASDAQ:PETX) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerf...Stansberry Research | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aratana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aratana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.